TY - JOUR T1 - Gut bacterial tyrosine decarboxylase gene abundance associates with disease duration, medication exposure, and gastrointestinal symptoms in a longitudinal cohort of Parkinson’s disease patients JF - medRxiv DO - 10.1101/2021.07.13.21259300 SP - 2021.07.13.21259300 AU - Sebastiaan P. van Kessel AU - Petri Auvinen AU - Filip Scheperjans AU - Sahar El Aidy Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/15/2021.07.13.21259300.abstract N2 - Gut microbiota influences the clinical response of a wide variety of orally administered drugs. However, the underlying mechanisms by which drug-microbiota interactions occur are still obscure. Previously, we reported that tyrosine decarboxylating (TDC) bacteria may restrict the levels of levodopa reaching the circulation in patients with Parkinson’s disease (PD). We observed a significant positive association between disease duration and the abundance of the bacterial tdc-gene. The question arises whether increased exposure to anti-PD medication could affect the abundance of bacterial TDC, to ultimately impact drug efficacy. To this end, we investigated the potential association between anti-PD drug exposure and bacterial tdc-gene abundance over a time period of two years in a longitudinal cohort of PD patients and healthy controls. Our data reveal significant associations between tdc-gene abundance, anti-PD medication, and gastrointestinal symptoms and warrants further research on the effect of anti-PD medication on microbial changes and gastrointestinal-function.Competing Interest StatementFS has patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd. FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics.Clinical TrialNCT01536769Funding StatementFS received funding from The Michael J. Fox Foundation for Parkinson's Research, The Finnish Parkinson Foundation, the Academy of Finland (295724, 310835), Helsinki University Hospital (T1010NL101, TYH2018224, TYH2020335), and Hyvinkää Hospital (M6095PEV12). FS has received consulting and lecture fees from Orion, Abbvie, Herantis, GE Healthcare, Merck, and Teva. SEA has acquired a research grant from Weston Brain Institute. The funders have no role in the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The original gender, age and sex matched cohort was recruited for a pilot study in 2015 investigating PD and gut microbiota (Scheperjans et al 2015). The study was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa. All participants gave written informed consent and the study was registered at clinicaltrials.gov (NCT01536769).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical data are not publicly available due to participant privacy and are available from the corresponding authors on reasonable request. ER -